Trial Profile
A prospective, double-blind, placebo-controlled, randomized single-escalating dose study of Roluperidone (MIN-101) in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Roluperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics; Pharmacokinetics
- 07 Dec 2018 New trial record
- 19 Nov 2018 Results presented in a Minerva Neurosciences media release.